Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
February 15, 2022 22:00 ET
|
Avenue Therapeutics
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Stock Trading Halted Today
February 15, 2022 07:05 ET
|
Avenue Therapeutics
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
December 15, 2021 12:00 ET
|
Avenue Therapeutics
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market,...
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock
December 12, 2021 20:00 ET
|
Avenue Therapeutics
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022
November 29, 2021 08:00 ET
|
Avenue Therapeutics
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue” or the “Company”), a company focused on the development of intravenous (“IV”) tramadol for the U.S....
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
November 17, 2021 09:30 ET
|
Avenue Therapeutics
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
November 12, 2021 09:20 ET
|
Avenue Therapeutics
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market,...
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
November 09, 2021 21:30 ET
|
Avenue Therapeutics
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
October 25, 2021 07:00 ET
|
Avenue Therapeutics
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
June 14, 2021 07:00 ET
|
Avenue Therapeutics
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...